Search and analyze individual stocks with comprehensive metrics
Shilpa Medicare Limited
Fundamental Score
Shilpa Medicare Limited Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SHILPAMED across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (18.80%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Robust Profit Growth (233.50%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Risk Factors
9 factors identified
Below-Average Return on Equity (4.21%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.82%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 61.74x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Weak Earnings Growth (-14.00% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-10.82% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Negative Free Cash Flow (₹-733.47 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
📊 Educational Market Overview
Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Shilpa Medicare Limited
About SHILPAMED
Company Details
Market Information
Performance
SHILPAMED Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of SHILPAMED?
SHILPAMED is currently trading at ₹365.20 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of SHILPAMED shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of SHILPAMED and what does it mean?
SHILPAMED has a P/E ratio of 61.74x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹62 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is SHILPAMED performing according to Bull Run's analysis?
SHILPAMED has a Bull Run fundamental score of 34.8/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 4.21%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does SHILPAMED belong to?
SHILPAMED operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Shilpa Medicare Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for SHILPAMED?
SHILPAMED has an ROE of 4.21%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Shilpa Medicare Limited generates profits from shareholders' equity. An ROE of 4% means the company generates ₹4 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is SHILPAMED's debt-to-equity ratio and what does it indicate?
SHILPAMED has a debt-to-equity ratio of 0.25, which indicates conservative financing with low financial risk. This means the company has ₹25 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is SHILPAMED's dividend yield and is it a good dividend stock?
SHILPAMED offers a dividend yield of 0.06%, which means you receive ₹0.06 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has SHILPAMED grown over the past 5 years?
SHILPAMED has achieved 5-year growth rates of: Sales Growth 7.12%, Profit Growth -10.82%, and EPS Growth -14.00%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in SHILPAMED and why does it matter?
Promoters hold 44.22% of SHILPAMED shares, with 7.92% of promoter shares pledged. This promoter holding level suggests balanced ownership between management and public shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does SHILPAMED compare with its industry peers?
SHILPAMED trades at P/E 61.74x vs industry average 33.97x, with ROE of 4.21% and ROCE of 7.82%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether SHILPAMED is outperforming its competitive set in profitability, growth, and valuation metrics.
What is SHILPAMED's market capitalization and what category does it fall into?
SHILPAMED has a market capitalization of ₹7937 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for SHILPAMED?
Key ratios for SHILPAMED: ROE 4.21% (Needs improvement), ROCE 7.82%, P/E 61.74x, Debt-to-Equity 0.25, Interest Coverage 3.43x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is SHILPAMED stock and what is its beta?
SHILPAMED has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for SHILPAMED?
SHILPAMED has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹365.20, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in SHILPAMED?
Key risks for SHILPAMED include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.25), and operational challenges. The stock has a Fundamental Score of 34.8/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is SHILPAMED's operating profit margin and how has it trended?
SHILPAMED has a 5-year average Operating Profit Margin (OPM) of 18.80%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.
How is SHILPAMED's quarterly performance in terms of sales and profit growth?
SHILPAMED's recent quarterly performance shows YoY Sales Growth of 9.90% and YoY Profit Growth of 233.50%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in SHILPAMED?
SHILPAMED has FII holding of 11.19% and DII holding of 7.46%, totaling 18.65% institutional ownership. This institutional participation level shows the confidence of professional money managers. Significant FII holding suggests global investor confidence and potential for index inclusion. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.